Journal Article

Surveillance and treatment of primary hepatocellular carcinoma (aka. STOP HCC): protocol for a prospective cohort study of high-risk patients for HCC using GALAD-score

Pham, Thuy Thi Thu, Nguyen, Van Thi, Mawardi, Mohammad, Alghamdi, Hamdan, Manal, Mohammed, Vaidya, Dhananjay, Hoang, Long Bao, Alqahtani, Saleh A., Pham, Hien Ba, Pham, Trang Ngoc Doan, Sanai, Faisal M., Dao, Diem Vu Bich, Nguyen, Linh Duc Duy, Alessy, Saleh, Truong, Thai Ngoc, Dao, Hang Viet, Nguyen, Khue, Siddiqui, Mohammed Amir, Nguyen, Nam Hai, Phan, Hai Thanh, Abaalkhail, Faisal, Johnson, Philip J., Dao, Doan Y, AlZahrani, May, Alswat, Khalid

2023

Overview

Background Vietnam and Saudi Arabia have high disease burden of primary hepatocellular carcinoma (HCC). Early detection in asymptomatic patients at risk for HCC is a strategy to improve survival outcomes in HCC management. GALAD score, a serum-based panel, has demonstrated promising clinical utility in HCC management. However, in order to ascertain its potential role in the surveillance of the early detection of HCC, GALAD needs to be validated prospectively for clinical surveillance of HCC (i.e., phase IV biomarker validation study). Thus, we propose to conduct a phase IV biomarker validation study to prospectively survey a cohort of patients with advanced fibrosis or compensated cirrhosis, irrespective of etiologies, using semi-annual abdominal ultrasound and GALAD score for five years. Methods We plan to recruit a cohort of 1,600 patients, male or female, with advanced fibrosis or cirrhosis (i.e., F3 or F4) and MELD ≤ 15, in Vietnam and Saudi Arabia ( n  = 800 each). Individuals with a liver mass ≥ 1 cm in diameter, elevated alpha-fetoprotein (AFP) (≥ 9 ng/mL), and/or elevated GALAD score (≥ -0.63) will be scanned with dynamic contrast-enhanced magnetic resonance imaging (MRI), and a diagnosis of HCC will be made by Liver Imaging Reporting and Data System (LiRADS) assessment (LiRADS-5). Additionally, those who do not exhibit abnormal imaging findings, elevated AFP titer, and/or elevated GALAD score will obtain a dynamic contrast-enhanced MRI annually for five years to assess for HCC. Only MRI nearest to the time of GALAD score measurement, ultrasound and/or AFP evaluation will be included in the diagnostic validation analysis. MRI will be replaced with an abdominal computed tomography scan when MRI results are poor due to patient conditions such as movement etc. Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced MRI will not be carried out in study sites in both countries. Bootstrap resampling technique will be used to account for repeated measures to estimate standard errors and confidence intervals. Additionally, we will use the Cox proportional hazards regression model with covariates tailored to the hypothesis under investigation for time-to-HCC data as predicted by time-varying biomarker data. Discussion The present work will evaluate the performance of GALAD score in early detection of liver cancer. Furthermore, by leveraging the prospective cohort, we will establish a biorepository of longitudinally collected biospecimens from patients with advanced fibrosis or cirrhosis to be used as a reference set for future research in early detection of HCC in the two countries. Trial registration Name of the registry: ClinicalTrials.gov Registration date: 22 April 2022 Trial registration number: NCT05342350 URL of trial registry record

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Archives & records / Biological markers / Biomarkers / Biomedical and Life Sciences / Biomedicine / Cancer / Cancer Research / Care and treatment / Cirrhosis / Cohort analysis / Computed tomography / Diagnosis / Drug therapy / Fibrosis / Gadolinium / GALAD score / Glycoproteins / HCC early detection / Health Promotion and Disease Prevention / Health surveillance / Hepatitis B / Hepatitis C / Hepatocellular carcinoma / Hepatology / Hepatoma / Hospitals / Informed consent / Liver / Liver cancer / Liver cirrhosis / Liver diseases / Magnetic resonance imaging / Medical protocols / Medical research / Medicine, Experimental / Medicine/Public Health / Military reserves / National health insurance / Oncology / Oncology, Experimental / Patients / Performance evaluation / Risk groups / Saudi Arabia / Study Protocol / Surgical Oncology / Surveys / Transplants & implants / Ultrasonic imaging / Ultrasound / Validation studies / Vietnam / α-Fetoprotein